SciBac

SciBac creates rEvolutionary live biotherapeutics that treat and prevent antibiotic resistant disease, while fortifying the microbiome. Using their proprietary platform technology, SciBac mates beneficial microbes to create hybrid strains with traits meticulously selected to target disease through multiple modes of action. SciBac has an expanding pipeline that includes biotherapeutics for Clostridium difficile infections and chronic Pseudomonas in cystic fibrosis patients.